ストックスクリーナーアプリを入手
503.90
0.06%
0.30
アフターアワーズ：
499.00
-4.90
-0.97%
前日終値:
$503.60
開ける：
$503.7
24時間の取引高:
607.44K
Relative Volume:
1.57
時価総額：
$21.70B
収益：
$3.13B
当期純損益:
$1.27B
株価収益率:
19.10
EPS:
26.3851
ネットキャッシュフロー:
$1.12B
1週間 パフォーマンス:
+6.44%
1か月 パフォーマンス:
+5.69%
6か月 パフォーマンス:
+65.03%
1年 パフォーマンス:
+55.71%
1日の値動き範囲:
$491.97
$507.93
1週間の範囲:
$466.00
$537.19
52週間の値動き範囲:
$266.98
$537.19
United Therapeutics Corp Stock (UTHR) Company Profile
名前
United Therapeutics Corp
セクター
電話
(301) 608-9292
住所
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
503.90 | 21.68B | 3.13B | 1.27B | 1.12B | 26.39 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.75 | 58.54B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
131.10 | 54.78B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.07 | 47.92B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.86 | 39.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Underweight |
| 2025-09-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | アップグレード | Goldman | Sell → Neutral |
| 2024-02-05 | 開始されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-12-05 | 開始されました | Goldman | Sell |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-20 | 繰り返されました | BofA Securities | Underperform |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Neutral |
| 2021-07-14 | アップグレード | Argus | Hold → Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-01 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-06-25 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-03-10 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-27 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-01-31 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 開始されました | BofA/Merrill | Underperform |
| 2019-08-01 | アップグレード | Jefferies | Underperform → Hold |
| 2019-08-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | アップグレード | UBS | Sell → Neutral |
| 2019-05-09 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | アップグレード | Standpoint Research | Hold → Buy |
| 2018-08-08 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 繰り返されました | Barclays | Underweight |
| 2018-01-18 | 再開されました | Credit Suisse | Underperform |
| 2017-12-27 | 繰り返されました | Wedbush | Outperform |
| 2017-04-27 | 繰り返されました | Wedbush | Outperform |
| 2017-03-30 | 開始されました | UBS | Sell |
| 2017-03-16 | 開始されました | Credit Suisse | Underperform |
すべてを表示
United Therapeutics Corp (UTHR) 最新ニュース
United Therapeutics Corp. Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics - Markets Mojo
United Therapeutics Corp. Hits New 52-Week High at $537.11 - Markets Mojo
H.C. Wainwright raises United Therapeutics stock price target to $600 - Investing.com Nigeria
United Therapeutics Hits Day High with 13% Surge in Strong Intraday Performance - Markets Mojo
United Therapeutics (NASDAQ:UTHR) Given New $600.00 Price Target at HC Wainwright - MarketBeat
These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings - Benzinga
Why United Therapeutics (UTHR) Shares Are Sliding Today - Finviz
Oppenheimer Raises United Therapeutics (UTHR) Price Target to $6 - GuruFocus
Wells Fargo Raises Price Target for United Therapeutics (UTHR) t - GuruFocus
MannKind’s Stock Plummets as United Therapeutics Unveils Rival Product - StocksToTrade
Wells Fargo & Company Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price - MarketBeat
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2025 Earnings Call Transcript - Insider Monkey
MANNKIND CORP SEC 10-K Report - TradingView
United Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus
TD Cowen raises United Therapeutics stock price target on growth outlook - Investing.com Nigeria
BofA raises United Therapeutics stock price target on earnings beat By Investing.com - Investing.com Canada
MannKind stock plummets after partner United Therapeutics unveils new 'category killer product' - MSN
United Therapeutics (NASDAQ:UTHR) Director Christopher Causey Sells 1,000 Shares - MarketBeat
United Therapeutics Corp (UTHR) Q4 2025 Earnings Call Highlights: Record Revenue and Promising Innovations - GuruFocus
United Therapeutics Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
BofA raises United Therapeutics stock price target on earnings beat - Investing.com
United Therapeutics (UTHR) Plans New Inhaler, Impacting MannKind (MNKD) and Liquidia (LQDA) - GuruFocus
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Asianet Newsable
Earnings call transcript: United Therapeutics beats Q4 2025 EPS estimates By Investing.com - Investing.com Canada
MannKind stock tumbles 37% on United Therapeutics inhaler news - Investing.com
United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates - Nasdaq
United Therapeutics (UTHR) Stock: Surges on Record $3.18B Revenue and Breakout Tyvaso Growth - CoinCentral
United Therapeutics Q4 2025 slides: EPS beat drives stock surge - Investing.com
MannKind (MNKD) Shares Plummet Amid United Therapeutics Announcement - GuruFocus
United Therapeutics Stock Rises 9% Over Increased Earnings In Q4 - Nasdaq
United Therapeutics stock hits all-time high at $520.00 - Investing.com
United Therapeutics Q4 2025 slides: EPS beat drives stock surge By Investing.com - Investing.com UK
Earnings call transcript: United Therapeutics beats Q4 2025 EPS estimates - Investing.com
United Therapeutics (NASDAQ:UTHR) Misses Q4 CY2025 Revenue Estimates - Finviz
UTHR Stock Price and Chart — NASDAQ:UTHR - TradingView
United Therapeutics Corp. (NASDAQ:UTHR) Reports Record Annual Revenue Despite Q4 Top-Line Miss - ChartMill
United Therapeutics Q4 Earnings Beat Expectations - Intellectia AI
United Therapeutics (UTHR) Surpasses EPS Expectations in Q4 - GuruFocus
United Therapeutics (UTHR) Reports Record Revenue but Misses Q4 Forecasts - GuruFocus
United Therapeutics: Fourth Quarter Earnings Overview - Bitget
United Therapeutics: Q4 Earnings Snapshot - marketscreener.com
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
United Therapeutics stock falls nearly 5% on revenue miss despite earnings beat - Investing.com
UNITED THERAPEUTICS Corp SEC 10-K Report - TradingView
United Therapeutics Corp Q4 Profit Rises - Nasdaq
Michael Benkowitz Sells 14,440 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
[Form 4] UNITED THERAPEUTICS Corp Insider Trading Activity - Stock Titan
United Therapeutics earnings up next: Tyvaso seasonality in focus - Investing.com
United Therapeutics Set to Announce Q4 Earnings on February 25 - Intellectia AI
Insights Ahead: United Therapeutics's Quarterly Earnings - Benzinga
United Therapeutics Corp (UTHR) 財務データ
収益
当期純利益
現金流量
EPS
United Therapeutics Corp (UTHR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| CAUSEY CHRISTOPHER | Director |
Feb 25 '26 |
Option Exercise |
119.76 |
1,000 |
119,760 |
5,190 |
| CAUSEY CHRISTOPHER | Director |
Feb 25 '26 |
Sale |
520.00 |
1,000 |
520,000 |
4,190 |
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Feb 23 '26 |
Option Exercise |
127.68 |
14,440 |
1,843,642 |
9,375 |
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Feb 23 '26 |
Sale |
472.13 |
14,440 |
6,817,499 |
0 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Feb 19 '26 |
Option Exercise |
146.03 |
8,300 |
1,212,049 |
45,081 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Feb 19 '26 |
Sale |
476.34 |
8,300 |
3,953,588 |
36,781 |
2.10%
1.23%
大文字化:
|
ボリューム (24 時間):